MyFinsight
Home
Blog
About
Contact
Back
Cash Flow
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)
source: myfinsight.com
Download
Download image
Proceeds from the
issuance of debt
$74,992K
Proceeds from the
exercise of stock options
$471K
Net cash provided by
financing activities
$75,463K
Net increase in cash
and cash...
$37,437K
Canceled cashflow
$38,026K
Accounts payable
$2,818K
Stock-based compensation
expense
$2,653K
Accretion of debt discount
and non-cash...
$732K
Depreciation and
amortization
$537K
Net cash used in
operating activities
-$38,026K
Canceled cashflow
$6,740K
Net loss
-$33,441K
Accrued expenses
-$10,187K
Prepaid expenses and
other current assets
$1,063K
Non-cash lease expense
-$851K
Back